Vertex Pharmaceuticals Incorporated
IT ˙ BIT ˙ US92532F1003
366,30 € ↓ -1,30 (-0,35%)
2026-06-03
AKTIENPREIS
SecurityIT:1VRTX / Vertex Pharmaceuticals Incorporated
InstitutionWaldron Private Wealth LLC
Latest Disclosed Ownership4,221 shares
Latest Disclosed Value $ 1,884,845
Waldron Private Wealth LLC reports 0.88% increase in ownership of 1VRTX / Vertex Pharmaceuticals Incorporated

On April 10, 2026 - Waldron Private Wealth LLC filed a 13F-HR form disclosing ownership of 4,221 shares of Vertex Pharmaceuticals Incorporated (IT:1VRTX) valued at $1,602,292 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 14, 2026 disclosing 4,184 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 0.88% during the quarter. The current value of the position is $1,546,152 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-04-10 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,221 37 0.88 1,885 -0.63 0.0735
2026-01-14 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,184 -116 -2.70 1,897 12.59 0.0750
2025-10-30 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,300 119 2.85 1,684 -9.51 0.0682
2025-07-31 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,181 -15 -0.36 1,861 -8.51 0.0812
2025-05-08 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,196 -690 -14.12 2,034 3.41 0.0960
2025-01-24 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,886 -197 -3.88 1,968 -16.76 0.0792
2024-10-21 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,083 78 1.56 2,364 0.77 0.0982
2024-07-31 2024-06-30 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,005 -115 -2.25 2,346 9.58 0.1050
2024-05-09 2024-03-31 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,120 7 0.14 2,140 2.88 0.0966
2024-08-29 2023-12-31 13F/A-1 VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,113 54 1.07 2,080 18.25 0.0989
2024-01-30 2023-12-31 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,113 54 2 0.0989
2024-08-29 2023-09-30 13F/A-1 VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,059 -33 -0.65 1,759 -1.79 0.0913
2023-10-26 2023-09-30 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,059 -33 2 0.0913
2024-08-29 2023-06-30 13F/A-1 VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,092 -449 -8.10 1,792 2.64 0.0894
2023-08-07 2023-06-30 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,092 -449 2 0.0894
2024-08-29 2023-03-31 13F/A-1 VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,541 -160 -2.81 1,746 174,400.00 0.0850
2023-05-02 2023-03-31 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,541 -160 2 0.0849
2023-02-08 2022-12-31 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,701 0 0.00 2 -99.94 0.1026
2022-11-14 2022-09-30 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,701 101 1.80 1,650 4.56 0.1025
2022-08-03 2022-06-30 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,600 159 2.92 1,578 11.21 0.0885
2022-05-04 2022-03-31 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,441 90 1.68 1,419 20.77 0.0728
2022-02-02 2021-12-31 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,351 -204 -3.67 1,175 16.68 0.0579
2021-11-02 2021-09-30 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,555 346 6.64 1,007 -4.10 0.0586
2021-08-06 2021-06-30 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,209 -2 -0.04 1,050 -6.17 0.0671
2021-05-11 2021-03-31 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,211 -75 -1.42 1,119 -10.41 0.0777
2021-02-12 2020-12-31 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,286 -17 -0.32 1,249 -13.44 0.0929
2020-11-13 2020-09-30 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,303 114 2.20 1,443 -4.18 0.1234
2020-08-11 2020-06-30 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,189 -233 -4.30 1,506 16.74 0.1331
2020-05-05 2020-03-31 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,422 15 0.28 1,290 9.04 0.1375
2020-02-07 2019-12-31 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,407 0 0.00 1,183 29.15 0.1054
2019-11-06 2019-09-30 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,407 0 0.00 916 -7.57 0.0933
2019-07-31 2019-06-30 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,407 113 2.13 991 1.85 0.1054
2019-05-01 2019-03-31 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 5,294 1,581 42.58 973 58.21 0.1096
2019-02-13 2018-12-31 13F Vertex Pharmaceuticals COM 92532F100 3,713 201 5.72 615 -9.02 0.0886
2018-11-20 2018-09-30 13F Vertex Pharmaceuticals COM 92532F100 3,512 3,512 676 0.1317
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.